Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
about
Current Landscape of Antiviral Drug DiscoveryEarly-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease preventionMolecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine TriphosphateBiochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA PolymeraseRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Viral aetiology of bronchiolitis in hospitalised children in Qatar.Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children.How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantationFerrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts.Baicalin from Scutellaria baicalensis blocks respiratory syncytial virus (RSV) infection and reduces inflammatory cell infiltration and lung injury in mice.Therapeutic efficacy of a respiratory syncytial virus fusion inhibitorProlonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus (RSV) infected infants.Respiratory syncytial virus: prospects for new and emerging therapeutics.Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.Latest options for treatment of bronchiolitis in infants.Structure-guided design of small-molecule therapeutics against RSV disease.Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients.Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants.Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.Antiviral therapy for respiratory viral infections in immunocompromised patients.Respiratory Syncytial Virus Infection: An Illness for All Ages.Factors predicting life-threatening infections with respiratory syncytial virus in adult patients.Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children.Ongoing developments in RSV prophylaxis: a clinician's analysis.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.Real-life comparison of three general paediatric wards showed similar outcomes for children with bronchiolitis despite different treatment regimens.Powerful Diagnostic Methods Applied to a Unique Specimen Collection.The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, versus its achievable concentrations in the human respiratory tract and comparison to ribavirin.Oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus.Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.ENHANCING THE THERMOSTABILITY AND IMMUNOGENICITY OF AN RSV LIVE-ATTENUATED VACCINE BY INCORPORATING UNIQUE RSV LINE19F PROTEIN RESIDUES.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Adherence and outcomes: a systematic review of palivizumab utilization.A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time.Respiratory syncytial virus is an "opportunistic" killer.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Nucleosides for the treatment of respiratory RNA virus infections.Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium.
P2860
Q26766639-31902B91-5FC6-4035-81E0-36464C1EE970Q28076551-BFCFDB82-649C-4AA7-9AF4-08FD2E46404CQ28548547-1FE27696-1FC1-4638-BC23-0343CBED3D98Q28551925-8D100E14-C356-4CCB-B399-C821ACF723DCQ30240274-208CC213-4DF8-42C2-8A29-0C489B16B552Q36279043-CCAECFBE-DD28-4114-80BE-A08DDB61CFB3Q36748198-C2832010-D3DE-4221-BC11-B321B1E25E7CQ36965855-A7DA6B77-FDC3-4BD4-8969-07FE1975CB86Q37049972-34E0F3C0-A1D2-408E-8A6D-A2B1FB3FFD29Q37355470-433FBCCF-1925-475B-B85F-6A8B978AC4DDQ38650711-E570A00D-7AB9-44F1-B433-0F9FAC8E57D0Q38671927-258A765B-7BE4-4FB3-BD49-DABD9930CB4BQ38675686-7C3276FB-4E16-433D-82B9-D1349058164BQ38742141-B9E44B67-454B-43FF-8169-93B74888993DQ38744226-3A42A518-EEF7-43BC-807A-77CA1F05872DQ38798541-58179BB5-B14E-47D0-8599-70718A376789Q38829076-E76CCE2B-689B-4E07-9A6D-1B3524261906Q38881879-804EB9C0-0B16-4F61-99E0-2A28B6043620Q39038875-564E1D6F-CF69-4DB4-BAFD-7CCFD0979616Q39076394-ADFD9687-0549-4FA2-9147-59CAF0678A7DQ39118423-0D727A6A-EA4E-4A6C-9E06-02FB9A4AFAF6Q39136472-EBF4D436-C7DD-471C-AE42-BAE487919000Q39294045-1B271807-E2AF-44CC-AF16-3662C1F87E3CQ39303791-2A7CD3E1-A29D-4CF1-9A28-EAF5BC409AADQ39444008-7DD233C1-AD24-4363-A3F4-BAC90B169449Q40144736-7343AF01-8A20-4A42-9E97-8EC6A5E9ED94Q40199531-5EC9CD29-CFC9-42EF-91FF-BA12D7C5D08CQ40262456-B8A79AB7-5229-401D-B39E-FB0A7F470EE0Q41921750-1D4CB552-6037-497C-8A49-8F2F1F77F4F7Q41927841-77E9AD9F-BFC4-4103-90F7-A8172EC44259Q45324676-6F0CF13D-E2C0-4B56-8FF1-38C52D4EB5EBQ47269161-619D97D0-AE94-45F2-AD89-86F84DE6088EQ47549703-10C9C733-E657-4A41-A5DE-40AE318926AFQ47582466-20951D3B-008B-48AA-A0F8-11D2A0AA986BQ48506169-886191DE-0419-4711-B3EB-6A456A880A59Q49817370-CE0829F7-DA06-4E61-BBA7-536F75A14751Q50262223-E69D25A7-5F3B-434B-84EC-3F8C2E11838DQ52644426-B84029B2-AA79-407C-9A4F-060B492CE7F8Q54248394-C4DDBC7A-4ECD-40CF-B5C1-C782C0EAAE43Q55400300-0EB09943-3353-4337-A63E-5720D36E12F5
P2860
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@ast
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@en
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@nl
type
label
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@ast
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@en
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@nl
prefLabel
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@ast
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@en
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@nl
P2093
P3181
P356
P1476
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
@en
P2093
Christopher Westland
Hosnieh Fathi
John P. DeVincenzo
Julian A. Symons
Lawrence M. Blatt
Leo Beigelman
Matthew W. McClure
Patrick Smith
Qingling Zhang
P304
P3181
P356
10.1056/NEJMOA1413275
P407
P577
2015-11-19T00:00:00Z